Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.58 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.57 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9932671 | 1.00 | SLC29A1 (0.58) | SLC29A1ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL28403790 | 0.88 | ADORA2A (0.58) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL6765506 | 0.86 | ADORA3 (0.49) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL2480941 | 0.81 | ADORA2A (0.62) | ADORA2AADORA2B | |
| SCHEMBL6474053 | 0.80 | SLC29A1 (0.68) | SLC29A1ADORA2AADORA2B | |
| SCHEMBL6474066 | 0.80 | SLC29A1 (0.68) | SLC29A1ADORA2AADORA2B | |
| SCHEMBL31307310 | 0.80 | SLC29A1 (0.67) | SLC29A1ADORA2AADORA2B | |
| SCHEMBL155837 | 0.80 | SLC29A1 (0.75) | SLC29A1ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL28477260 | 0.80 | ADORA2A (0.67) | SLC29A1ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL155836 | 0.80 | SLC29A1 (0.75) | SLC29A1ADORA2AADORA2BADORA1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705481-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | Orna Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4705468-A1 | MAMMALIAN POLYCISTRONIC EXPRESSION SYSTEM FOR DIRECT TRANSLATION FROM RNA AND SECRETION OF CARGO | California Institute of Technology (US) | 2026-03-11 | — | — | EP | claimed |
| WO-2024233308-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. (US) | 2024-11-14 | — | — | WO | claimed |
| WO-2024229296-A1 | MAMMALIAN POLYCISTRONIC EXPRESSION SYSTEM FOR DIRECT TRANSLATION FROM RNA AND SECRETION OF CARGO | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2024-11-07 | — | — | WO | claimed |
| EP-4334446-A1 | IMPROVED NUCLEIC ACID SEQUENCE FOR CELL TYPE SPECIFIC EXPRESSION | CureVac SE (DE) | 2024-03-13 | — | — | EP | claimed |
| WO-2022233880-A1 | IMPROVED NUCLEIC ACID SEQUENCE FOR CELL TYPE SPECIFIC EXPRESSION | CUREVAC AG (DE) | 2022-11-10 | — | — | WO | claimed |
| EP-4013880-A1 | RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES | CureVac AG (DE) | 2022-06-22 | — | — | EP | claimed |
| EP-4747380-A1 | MODULATING EXPRESSION OF ALAS1 (5'-AMINOLEVULINATE SYNTHASE 1) GENE | CRISPR Therapeutics AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026107055-A1 | HEPATITIS B VIRUS VACCINE AND METHODS OF USE | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4735033-A2 | MRNA-ENCODED TAT WITH ATTENUATED CYTOTOXICITY FOR HIV AND SIV LATENCY REVERSAL | The Trustees of the University of Pennsylvania (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4727955-A1 | CYSTEINE-SUBSTITUTED RSV-F PROTEINS | GlaxoSmithKline Biologicals S.A. (BE) | 2026-04-22 | — | — | EP | disclosed |
| EP-4709417-A2 | POLYNUCLEOTIDES ENCODING NOROVIRUS VP1 ANTIGENS AND USES THEREOF | Merck Sharp & Dohme LLC (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4705468-A1 | MAMMALIAN POLYCISTRONIC EXPRESSION SYSTEM FOR DIRECT TRANSLATION FROM RNA AND SECRETION OF CARGO | California Institute of Technology (US) | 2026-03-11 | — | — | EP | disclosed |
| WO-2022155421-A1 | STAPHYLOCOCCUS AUREUS ANTIGEN-BASED NUCLEIC ACID VACCINES | UNIVERSITY OF ROCHESTER (US) | 2022-07-21 | — | — | WO | disclosed |
| EP-4013880-A1 | RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES | CureVac AG (DE) | 2022-06-22 | — | — | EP | disclosed |
| US-11339441-B2 | Profiling chemically modified DNA/RNA units for disease and cancer diagnosis | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2022-05-24 | — | — | US | disclosed |
| WO-2022096582-A1 | USE OF IFN-LAMBDA MRNA FOR TREATING VIRAL INFECTIONS | ETHRIS GMBH (DE) | 2022-05-12 | — | — | WO | disclosed |
| WO-2022081699-A1 | IN VIVO TARGETING OF T CELLS FOR MRNA THERAPEUTICS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022081702-A1 | IN VIVO TARGETING OF CD4+-T CELLS FOR MRNA THERAPEUTICS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022081694-A1 | IN VIVO TARGETING OF FIBROSIS BY ANTI-CD5-TARGETED FAP-CAR T MRNA-LNP | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2022-04-21 | — | — | WO | disclosed |